The aim of this study was to assess the influence of the CYP2D6 and CYP1A2 gene polymorphisms on the efficacy of duloxetine treatment in reducing depressive and anxiety symptoms among patients with MDD. Here, CYP1A2 is linked to major depressive disorder.